Canaccord analyst John Young raised the firm’s price target on Merit Medical (MMSI) to $112 from $108 and keeps a Buy rating on the shares. The firm noted their announced acquisition of BioLife and the company’s reaffirmation of its FY25 guidance, and updated it to reflect the anticipated impact from the merger.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target raised to $108 from $106 at Wells Fargo
- Merit Medical Acquires Biolife Delaware for $120 Million
- Merit Medical’s Strategic Acquisition of Biolife Delaware: A Long-Term Growth Catalyst
- Merit Medical adjusts FY25 EPS view to $3.28-$3.41 from $3.29-$3.42
- Merit Medical acquires Biolife Delaware